中国实用医刊
中國實用醫刊
중국실용의간
CENTRAL PLAINS MEDICAL JOURNAL
2011年
14期
50-52
,共3页
阿托伐他汀%脑梗死%超敏C反应蛋白%白细胞介素-6
阿託伐他汀%腦梗死%超敏C反應蛋白%白細胞介素-6
아탁벌타정%뇌경사%초민C반응단백%백세포개소-6
Atorvastatin%Cerebral infarction%High-sensitivity C-reactive protein%Interleukin-6
目的 探讨阿托伐他汀对急性脑梗死(ACI)患者血清超敏C反应蛋白(hs-CRP)及白细胞介素-6(IL-6)水平以及神经功能的影响.方法 将80例ACI患者随机分为阿托伐他汀组(40例)和常规治疗组(40例).阿托伐他汀组在常规治疗基础上加用阿托伐他汀20 mg,每日1次,连续服用4周.检测治疗前后血清hs-CRP和IL-6水平,并进行神经功能缺损程度评分(NDS)评定.并以20例健康体检者作为正常对照组.结果 ACI患者血清hs-CRP和IL-6水平较正常对照组明显升高(P<0.05);治疗后两组血清hs-CRP和IL-6水平均较治疗前明显下降(均P<0.05),且阿托伐他汀组较常规治疗组下降明显(P<0.05);两组NDS评分较治疗前明显下降(均P<0.05),且阿托伐他汀组较常规治疗组下降明显(P<0.05).结论 阿托伐他汀能明显降低ACI患者血清hs-CRP和IL-6水平,并有助于ACI患者的神经功能恢复.
目的 探討阿託伐他汀對急性腦梗死(ACI)患者血清超敏C反應蛋白(hs-CRP)及白細胞介素-6(IL-6)水平以及神經功能的影響.方法 將80例ACI患者隨機分為阿託伐他汀組(40例)和常規治療組(40例).阿託伐他汀組在常規治療基礎上加用阿託伐他汀20 mg,每日1次,連續服用4週.檢測治療前後血清hs-CRP和IL-6水平,併進行神經功能缺損程度評分(NDS)評定.併以20例健康體檢者作為正常對照組.結果 ACI患者血清hs-CRP和IL-6水平較正常對照組明顯升高(P<0.05);治療後兩組血清hs-CRP和IL-6水平均較治療前明顯下降(均P<0.05),且阿託伐他汀組較常規治療組下降明顯(P<0.05);兩組NDS評分較治療前明顯下降(均P<0.05),且阿託伐他汀組較常規治療組下降明顯(P<0.05).結論 阿託伐他汀能明顯降低ACI患者血清hs-CRP和IL-6水平,併有助于ACI患者的神經功能恢複.
목적 탐토아탁벌타정대급성뇌경사(ACI)환자혈청초민C반응단백(hs-CRP)급백세포개소-6(IL-6)수평이급신경공능적영향.방법 장80례ACI환자수궤분위아탁벌타정조(40례)화상규치료조(40례).아탁벌타정조재상규치료기출상가용아탁벌타정20 mg,매일1차,련속복용4주.검측치료전후혈청hs-CRP화IL-6수평,병진행신경공능결손정도평분(NDS)평정.병이20례건강체검자작위정상대조조.결과 ACI환자혈청hs-CRP화IL-6수평교정상대조조명현승고(P<0.05);치료후량조혈청hs-CRP화IL-6수평균교치료전명현하강(균P<0.05),차아탁벌타정조교상규치료조하강명현(P<0.05);량조NDS평분교치료전명현하강(균P<0.05),차아탁벌타정조교상규치료조하강명현(P<0.05).결론 아탁벌타정능명현강저ACI환자혈청hs-CRP화IL-6수평,병유조우ACI환자적신경공능회복.
Objective To explore the effect of atorvastatin on the level of serum high sensitivity C-reactive protein (hs-CRP) and interleukin-6(IL-6) in patients with acute cerebral infarction(ACI). Methods Eighty patients with ACI were randomly divided into the atorvastatin therapy group(n=40) and the conventional therapy group (n=40). At the basic of conventional therapy, the atorvastatin therapy group was treated with atorvastatin 20 mg/d. Both groups were treated for 4 weeks. The levels of serum hs-CRP and IL-6 were measured and the scores of neurological deficit(NDS) were evaluated before and after treatment. A healthy control group which approximately matched the experimental group included 20 cases. Results The levels of serum hs-CRP and IL-6 in both two groups after 14 d treatment were significantly lower than those before treatment (all P<0.05), and the level of serum hs-CRP and IL-6 in atorvastatin therapy group was significantly lower than that in conventional therapy group (P<0.05). NDS of both groups after treatment were lower than those before treatment (P<0 05), and the scores of atorvastatin therapy group were significantly lower than those of conventional therapy group (P<0.05). Conclusions Atorvastatin can significantly decrease the level of serum hs-CRP and IL-6, and it can promote the neurological fuction recovery in the patients with ACI.
